Fervaha Gagan, Hill Christina, Agid Ofer, Takeuchi Hiroyoshi, Foussias George, Siddiqui Ishraq, Kern Robert S, Remington Gary
Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Canada; Institute of Medical Science, University of Toronto, Toronto, Canada.
Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Canada.
Schizophr Res. 2015 Aug;166(1-3):304-9. doi: 10.1016/j.schres.2015.05.015. Epub 2015 May 23.
Although many comprehensive batteries exist to evaluate the nature and degree of cognitive impairments in patients with schizophrenia, short batteries hold promise for rapidly screening and estimating deficits in global cognition. Recently, the Brief Neurocognitive Assessment (BNA) was established and has been shown to have similar validity and utility to a more comprehensive battery of cognitive tests in evaluating global cognitive impairments in patients with schizophrenia. The present study sought to further establish the validity of the BNA by comparing it with the MATRICS Consensus Cognitive Battery (MCCB).
One-hundred seventy-six patients with schizophrenia and 300 healthy volunteers participated in the present study. Global cognition was evaluated using the MCCB composite score and estimated using the BNA. To examine practice effects and test-retest reliability, patients were re-assessed after 4weeks.
The BNA was highly correlated with global cognition as evaluated by the MCCB in both the schizophrenia (r=0.82) and healthy control samples (r=0.75). Both instruments were similarly sensitive to deficits in global cognition in patients with schizophrenia relative to healthy controls. The BNA also demonstrated high test-retest reliability in patients with schizophrenia (r=0.87), comparable to the level observed with the MCCB (r=0.91). In addition, both the BNA and MCCB showed a similar level of practice effects (both Cohen's d=0.11), and both instruments demonstrated equivalent sensitivities to longitudinal change. Furthermore, scores from the BNA and MCCB were related to symptom severity and functional capacity to a similar degree.
The BNA provides clinicians and researchers with an efficient and reliable means by which to evaluate global neurocognitive impairments in patients with schizophrenia by allowing estimation of performance on a more comprehensive standardized battery.
尽管存在许多综合测试组合来评估精神分裂症患者认知障碍的性质和程度，但简短的测试组合有望快速筛查和评估整体认知缺陷。最近，简短神经认知评估（BNA）已被确立，并且在评估精神分裂症患者的整体认知障碍方面，已显示出与更全面的认知测试组合具有相似的效度和效用。本研究旨在通过将BNA与MATRICS共识认知测试组合（MCCB）进行比较，进一步确立BNA的效度。
176名精神分裂症患者和300名健康志愿者参与了本研究。使用MCCB综合评分评估整体认知，并使用BNA进行估计。为了检验练习效应和重测信度，4周后对患者进行重新评估。
在精神分裂症患者（r = 0.82）和健康对照样本（r = 0.75）中，BNA与通过MCCB评估的整体认知高度相关。相对于健康对照，这两种工具对精神分裂症患者的整体认知缺陷同样敏感。BNA在精神分裂症患者中也显示出较高的重测信度（r = 0.87），与MCCB观察到的水平相当（r = 0.91）。此外，BNA和MCCB都显示出相似水平的练习效应（Cohen's d均为0.11），并且两种工具对纵向变化的敏感性相当。此外，BNA和MCCB的分数与症状严重程度和功能能力的相关程度相似。
BNA为临床医生和研究人员提供了一种有效且可靠的方法，通过允许估计在更全面的标准化测试组合上的表现，来评估精神分裂症患者的整体神经认知障碍。
